Article Correctness Is Author's Responsibility: ASCO: Entrectinib gets edge over crizotinib against ROS1+ lung cancer

(University of Colorado Anschutz Medical Campus) Median time to treatment discontinuation (TTD) on crizotinib was 8.8 months; TTD of patients using entrectinib was 14.6 months. Compared with patients on entrectinib, patients on crizotinib had an additional 44 percent chance that their cancer would resume its growth.